Menu Search
Equities

Algorae Pharmaceuticals Ltd

LHI0:DEU

Algorae Pharmaceuticals Ltd

Actions
  • Price (EUR)0.006
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of May 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Algorae Pharmaceuticals Limited, formerly Living Cell Technologies Limited, is an Australia-based pharmaceutical development company. The Company is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.

  • Revenue in AUD (TTM)84.10k
  • Net income in AUD-2.25m
  • Incorporated2003
  • Employees--
  • Location
    Algorae Pharmaceuticals LtdLevel 23,, Rialto South Tower,,525 Collins Street,MELBOURNE 3000AustraliaAUS
  • Phone+61 28999-0970
  • Fax+61 41793-5552
  • Websitehttps://lctglobal.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.